dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Garrido, Pilar |
dc.contributor.author | Adjei, A. A. |
dc.contributor.author | Bajpai, J. |
dc.contributor.author | Berghoff, A. S. |
dc.contributor.author | Choo, S. P. |
dc.contributor.author | Felip Font, Enriqueta |
dc.contributor.author | Garralda Cabanas, Elena |
dc.contributor.author | Tabernero Caturla, Josep |
dc.contributor.author | Banerjee, Susana |
dc.date.accessioned | 2022-02-23T06:49:57Z |
dc.date.available | 2022-02-23T06:49:57Z |
dc.date.issued | 2021-06 |
dc.identifier.citation | Garrido P, Adjei AA, Bajpai J, Banerjee S, Berghoff AS, Choo SP, et al. Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey. ESMO Open. 2021 Jun;6(3):100131. |
dc.identifier.issn | 2059-7029 |
dc.identifier.uri | https://hdl.handle.net/11351/7072 |
dc.description | Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Desigualtats; Dona |
dc.description.sponsorship | This work was supported by the European Society for Medical Oncology (ESMO). |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | ESMO Open;6(3) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Pandèmia de COVID-19, 2020- |
dc.subject | Oncologia |
dc.subject | Qüestionaris |
dc.subject.mesh | Coronavirus Infections |
dc.subject.mesh | Oncologists |
dc.subject.mesh | Surveys and Questionnaires |
dc.title | Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.esmoop.2021.100131 |
dc.subject.decs | infecciones por Coronavirus |
dc.subject.decs | oncólogos |
dc.subject.decs | encuestas y cuestionarios |
dc.relation.publishversion | https://doi.org/10.1016/j.esmoop.2021.100131 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Garrido P] Universidad de Alcalá, Medical Oncology Department, IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain. [Adjei AA] Mayo Clinic, Rochester, USA. [Bajpai J] Tata Memorial Centre, Mumbai, India. [Banerjee S] The Royal Marsden NHS Foundation Trust, Institute of Cancer Research, London, UK. [Berghoff AS] Division of Oncology, Department of Medicine 1, Medical University of Vienna, Vienna, Austria. [Choo SP] Curie Oncology Singapore, National Cancer Centre Singapore, Singapore. [Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Thoracic Oncology and H&N Cancer Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVic-UCC, Barcelona, Spain. [Garralda E] Early Drug Development Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVic-UCC, Barcelona, Spain |
dc.identifier.pmid | 34144778 |
dc.identifier.wos | 000663044500027 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |